Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of “Hold” by Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have been given a consensus rating of “Hold” by the six research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $30.75.

Several equities research analysts recently issued reports on PCRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Pacira BioSciences in a report on Friday, January 9th. Barclays initiated coverage on shares of Pacira BioSciences in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $27.00 target price on the stock. Wall Street Zen upgraded shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a research note on Friday, January 9th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th.

Pacira BioSciences Price Performance

Shares of PCRX stock opened at $23.22 on Monday. Pacira BioSciences has a twelve month low of $18.80 and a twelve month high of $27.64. The company has a quick ratio of 3.78, a current ratio of 5.26 and a debt-to-equity ratio of 0.52. The business has a fifty day simple moving average of $23.00 and a 200 day simple moving average of $23.90. The company has a market cap of $998.92 million, a P/E ratio of 51.60 and a beta of 0.25.

Insider Activity

In other Pacira BioSciences news, SVP Lauren Riker sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the transaction, the senior vice president directly owned 52,313 shares in the company, valued at approximately $1,088,633.53. This represents a 7.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Shawn Cross sold 9,104 shares of the firm’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $25.14, for a total transaction of $228,874.56. Following the transaction, the chief financial officer directly owned 56,250 shares of the company’s stock, valued at $1,414,125. The trade was a 13.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 30,416 shares of company stock worth $744,315. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Hussman Strategic Advisors Inc. bought a new stake in shares of Pacira BioSciences during the 3rd quarter valued at about $2,706,000. Exchange Traded Concepts LLC acquired a new position in shares of Pacira BioSciences during the 3rd quarter valued at $1,948,000. Impax Asset Management Group plc boosted its stake in Pacira BioSciences by 27.7% during the third quarter. Impax Asset Management Group plc now owns 600,027 shares of the company’s stock worth $15,463,000 after acquiring an additional 130,000 shares in the last quarter. American Century Companies Inc. increased its stake in Pacira BioSciences by 77.2% in the second quarter. American Century Companies Inc. now owns 1,182,513 shares of the company’s stock valued at $28,262,000 after purchasing an additional 515,090 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in shares of Pacira BioSciences during the second quarter valued at about $2,454,000. 99.73% of the stock is owned by institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.